Aug 10, 2026 09:01AM
Aug 10, 2026 09:00AM
Aug 4, 2026 07:30AM
Jul 30, 2026 04:53AM
Jul 29, 2026 06:45PM
Jun 1, 2026 01:53PM
Jun 1, 2026 01:51PM ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
May 21, 2026 04:28PM
May 20, 2026 02:18PM
May 19, 2026 08:30PM
May 19, 2026 08:30PM
May 19, 2026 02:16PM
May 19, 2026 07:31AM
May 19, 2026 07:30AM ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
May 18, 2026 01:01PM
May 18, 2026 07:31AM
May 18, 2026 07:30AM
May 16, 2026 01:35PM
May 16, 2026 01:35PM
May 7, 2026 09:00AM
May 7, 2026 07:30AM ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash
Apr 6, 2026 07:30AM
Apr 6, 2026 07:30AM
Mar 31, 2026 07:31AM
Mar 31, 2026 07:30AM
Mar 26, 2026 07:30AM
Mar 26, 2026 07:30AM
Mar 24, 2026 12:52PM BTIG on Immunitybio Inc (IBRX): FDA warning letter issue 'likely resolvable,' selloff a buying oppty
Mar 24, 2026 10:44AM
Mar 24, 2026 09:27AM
Mar 20, 2026 01:08PM
Mar 20, 2026 01:08PM
Mar 17, 2026 07:31AM
Mar 17, 2026 07:30AM
Mar 9, 2026 07:31AM ImmunityBio resubmits cancer treatment application to FDA
Mar 9, 2026 07:30AM
Mar 4, 2026 07:54AM
Feb 26, 2026 07:31AM
Feb 26, 2026 07:30AM
Feb 23, 2026 04:15PM
Feb 23, 2026 09:36AM
Feb 23, 2026 07:01AM ImmunityBio reports 700% revenue growth, expands approvals globally
Feb 23, 2026 07:00AM
Feb 20, 2026 08:30AM
Feb 20, 2026 08:30AM
Feb 19, 2026 09:02AM
Feb 19, 2026 09:00AM
Feb 18, 2026 09:01AM
Feb 18, 2026 09:00AM ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries
Feb 17, 2026 06:09AM

328,334 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All